Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis

• Status: Completed
• Trial end date: 2013-06-17
• Target enrollment: 0
• Participant gender: All

Summary

This was a Phase I, single-center, randomized, controlled trial to evaluate the antipsoriatic efficacy of calcipotriol in novel formulations based on AKVANO technology as compared to marketed calcipotriol products (Daivonex® solution and cream) and to evaluate their cutaneous safety in a psoriasis plaque test

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lipidor AB
• Collaborator: Bioskin GmbH
• Treatments: Calcipotriene; Calcitriol

Criteria

Inclusion Criteria:

All of the following criteria had to be met for inclusion of a subject in the clinical trial:

• Subjects with psoriasis vulgaris in a chronic stable phase and mild or moderate plaque(s) with up to three plaque areas sufficient for six treatment fields

• The target lesion(s) should have been on the trunk or extremities (excluding palms/soles); psoriatic lesion on the knees were not used as a target lesion

• Plaques to be treated should have had a comparable psoriatic infiltrate thickness of at least 200 μm

• The physical examination of the skin had to be without disease findings unless the investigator considered an abnormality to be irrelevant to the outcome of the clinical trial

• Female volunteers of childbearing potential had to be either surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1 % per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices [IUDs], sexual abstinence or had a vasectomized partner

• Written informed consent obtained

Exclusion Criteria:

Subjects were excluded from the clinical trial when one or more of the following conditions were met:

• Other skin disease noted on physical examination that was considered by the investigator to be relevant to the outcome of the trial;

• Subjects with psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, psoriasis arthropathica and pustular psoriasis

• Any topical antipsoriatic treatment on the plaques to be treated in this trial (including corticosteroids, except for salicylic acid) in the three months before first treatment and/or during the trial

• Systemic treatment with antipsoriatics e.g. corticosteroids, cytostatics, retinoids in the three months before first treatment and during the trial

• Treatment with systemic or locally acting medications which might have countered or influenced the trial aim (medications which were known to provoke or aggravate psoriasis, e.g. ß-blocker, antimalarial drugs, lithium) within three months before first treatment and/or during the trial

• Known allergic reactions irritations or sensitivity to the active ingredients or other components of the investigational products;

• Contraindications according to summary of product characteristics of Daivonex®

• Evidence of drug or alcohol abuse

• Pregnancy or nursing

• UV-therapy within four weeks before first treatment and during the trial

• Symptoms of a clinically significant illness that might have influenced the outcome of the trial in the four weeks before first treatment and during the trial

• Participation in the treatment phase of another clinical trial within the last four weeks prior to the first treatment in this clinical trial

• In the opinion of the investigator or physician performing the initial examination the subject should not have participated in the clinical trial, e.g. due to probable non-compliance or inability to understand the trial and give adequately informed consent

• Close affiliation with the investigator (e.g. a close relative) or persons working at bioskin GmbH or subject was an employee of sponsor

• Subject was institutionalized because of legal or regulatory order